Media Articles Related to Levatol (Penbutolol)
New Hypertension After 80 Linked to Lower Dementia Risk
Source: Medscape NeurologyHeadlines [2014.07.14]
New results from the 90+ Study show new hypertension after 80 years of age not only doesn't increase dementia risk but is actually associated with reduced risk.
Medscape Medical News
Treatment-resistant hypertension requires proper diagnosis
Source: Hypertension News From Medical News Today [2014.07.09]
High blood pressure - also known as hypertension - is widespread, but treatment often fails. One in five people with hypertension does not respond to therapy.
Hypertension, antihypertension medication and risk of psoriasis
Source: Hypertension News From Medical News Today [2014.07.04]
Women with long-term high blood pressure (hypertension) appear to be at an increased risk for the skin condition psoriasis, and long-term use of beta (β)-blocker medication to treat hypertension...
Risk of hypertension increased in pregnancies resulting from egg donation
Source: Fertility News From Medical News Today [2014.07.02]
With an ever-ageing female patient population, egg donation is an increasingly common treatment in infertility.
Genetic study suggests causal link between vitamin D deficiency and hypertension
Source: Hypertension News From Medical News Today [2014.06.27]
New genetic research provides compelling evidence that low levels of vitamin D have a causal role in the development of high blood pressure (hypertension).
Published Studies Related to Levatol (Penbutolol)
[The noninvasive assessment of the effects of penbutolol on liver hemodynamics in cirrhotic patients using angioscintigraphy. A randomized controlled double-blind study] [1990.11]
This randomized double-blind controlled study analyzed the hemodynamic effects of penbutolol, a new levo-rotatory betablocker, using radionuclide angiography. Twenty cirrhotics with esophageal varices were randomized: 10 received 40 mg/day of penbutolol orally and the others a placebo...
The influence of penbutolol and placebo on blood sugar levels and insulin consumption in the glucose-controlled insulin infusion system ("artificial endocrine pancreas"). [1990.10.03]
The aim of the study was to investigate the influence of 40 mg of the beta-blocker penbutolol (Betapressin TM; Hoechst Ltd., Frankfurt/Main) in comparison to placebo on the insulin consumption on the blood sugar profile in twelve insulin-dependent diabetes (IDDM) patients...
Angioscintigraphic assessment of hemodynamic effects of penbutolol in cirrhotics with portal hypertension. A double-blind, randomized, controlled study. [1990.08]
This randomized double-blind controlled study analyzed the hemodynamic effects of penbutolol, a new levorotatory beta-blocker, using radionuclide angiography. Twenty cirrhotics with esophageal varices were randomized to two groups: 10 received 40 mg/day of penbutolol orally and the others placebo...
Penbutolol in the treatment of mild to moderate essential hypertension in black South Africans. [1990.06]
The antihypertensive effects of penbutolol, a nonselective beta-adrenoceptor antagonist with intrinsic sympathomimetic activity, was assessed in nonobese black South Africans aged 25 to 65 years with uncomplicated mild to moderate essential hypertension...
Effects of penbutolol on plasma atrial natriuretic peptide and antidiuretic hormone levels before and after exercise: a double-blind comparison against placebo. 
A double-blind crossover trial was carried out in 7 healthy male volunteers to investigate the effects of penbutolol and a placebo on plasma atrial natriuretic peptide (ANP) and antidiuretic hormone (ADH) levels before and after exercise. Each subject underwent several bicycle ergometric exercises lasting 6 min before and after the application of test medications...
Clinical Trials Related to Levatol (Penbutolol)
Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension [Completed]
Plasma renin values determine whether volume or vasoconstrictor (renin) factors predominate
in elevating blood pressure and are useful in selecting effective antihypertensive
The researchers hypothesize that:
1. Plasma renin-guided therapeutics will improve systolic and diastolic blood pressure
control in patients with untreated hypertension as well as in patients with treatment
refractory or resistant hypertension that are managed by Clinical Hypertension
2. Renin-guided therapeutics will reduce the number of medications required to maintain
blood pressure control to <140/90 mmHg in hypertensive patients receiving 3 or more
medications, while under the care of a Clinical Hypertension Specialist.
3. Renin-guided therapeutics selection will reduce the total cost of antihypertensive care
provided by Clinical Hypertension Specialists.